Wan X - Search Results

1

Cost-effectiveness of atezolizumab plus bevacizumab as first-line therapy for metastatic renal cell carcinoma.

Wang S, Xie O, Wu M, Xiang H, Tan C, Wan X. Wang S, et al. Among authors: wan x. Expert Rev Pharmacoecon Outcomes Res. 2024 Sep 1:1-6. doi: 10.1080/14737167.2024.2399246. Online ahead of print. Expert Rev Pharmacoecon Outcomes Res. 2024. PMID: 39215475

2

The cost of treating advanced non-small cell lung cancer: estimates from the chinese experience.

Zeng X, Karnon J, Wang S, Wu B, Wan X, Peng L. Zeng X, et al. Among authors: wan x. PLoS One. 2012;7(10):e48323. doi: 10.1371/journal.pone.0048323. Epub 2012 Oct 31. PLoS One. 2012. PMID: 23118985 Free PMC article.

3

Cost-effectiveness of continuation maintenance pemetrexed after cisplatin and pemetrexed chemotherapy for advanced nonsquamous non-small-cell lung cancer: estimates from the perspective of the Chinese health care system.

Zeng X, Peng L, Li J, Chen G, Tan C, Wang S, Wan X, Ouyang L, Zhao Z. Zeng X, et al. Among authors: wan x. Clin Ther. 2013 Jan;35(1):54-65. doi: 10.1016/j.clinthera.2012.12.013. Clin Ther. 2013. PMID: 23328269

4

Economic evaluation of first-line adjuvant chemotherapies for resectable gastric cancer patients in China.

Tan C, Peng L, Zeng X, Li J, Wan X, Chen G, Yi L, Luo X, Zhao Z. Tan C, et al. Among authors: wan x. PLoS One. 2013 Dec 10;8(12):e83396. doi: 10.1371/journal.pone.0083396. eCollection 2013. PLoS One. 2013. PMID: 24340099 Free PMC article.

5

Economic outcomes of maintenance gefitinib for locally advanced/metastatic non-small-cell lung cancer with unknown EGFR mutations: a semi-Markov model analysis.

Zeng X, Li J, Peng L, Wang Y, Tan C, Chen G, Wan X, Lu Q, Yi L. Zeng X, et al. Among authors: wan x. PLoS One. 2014 Feb 20;9(2):e88881. doi: 10.1371/journal.pone.0088881. eCollection 2014. PLoS One. 2014. PMID: 24586426 Free PMC article.

6

Ribociclib in hormone-receptor-positive advanced breast cancer: Establishing a value-based cost in China.

Wan X, Zhang Y, Ma J, Tan C, Zeng X, Peng L. Wan X, et al. Breast. 2019 Feb;43:1-6. doi: 10.1016/j.breast.2018.10.004. Epub 2018 Oct 16. Breast. 2019. PMID: 30342258

7

First-line Nivolumab Plus Ipilimumab vs Sunitinib for Metastatic Renal Cell Carcinoma: A Cost-effectiveness Analysis.

Wan X, Zhang Y, Tan C, Zeng X, Peng L. Wan X, et al. JAMA Oncol. 2019 Apr 1;5(4):491-496. doi: 10.1001/jamaoncol.2018.7086. JAMA Oncol. 2019. PMID: 30789633 Free PMC article. Clinical Trial.

8

Cost-effectiveness Analysis of Pembrolizumab Plus Axitinib Versus Sunitinib in First-line Advanced Renal Cell Carcinoma in China.

Chen J, Hu G, Chen Z, Wan X, Tan C, Zeng X, Cheng Z. Chen J, et al. Among authors: wan x. Clin Drug Investig. 2019 Oct;39(10):931-938. doi: 10.1007/s40261-019-00820-6. Clin Drug Investig. 2019. PMID: 31250401

9

First-line atezolizumab in addition to bevacizumab plus chemotherapy for metastatic, nonsquamous non-small cell lung cancer: A United States-based cost-effectiveness analysis.

Wan X, Luo X, Tan C, Zeng X, Zhang Y, Peng L. Wan X, et al. Cancer. 2019 Oct 15;125(20):3526-3534. doi: 10.1002/cncr.32368. Epub 2019 Jul 9. Cancer. 2019. PMID: 31287562 Free article.

10

Model-Based Economic Evaluation of Ceritinib and Platinum-Based Chemotherapy as First-Line Treatments for Advanced Non-Small Cell Lung Cancer in China.

Peng Y, Ma F, Tan C, Wan X, Yi L, Peng L, Zeng X. Peng Y, et al. Among authors: wan x. Adv Ther. 2019 Nov;36(11):3047-3058. doi: 10.1007/s12325-019-01103-4. Epub 2019 Oct 1. Adv Ther. 2019. PMID: 31576479

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

6,162 results

Search Page

Filters